Related Experiment Video

Updated: May 21, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease

Peter McColgan1, Jonathan R Evans, David P Breen

  • 1Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom. pmccolgan02@qub.ac.uk

Movement Disorders : Official Journal of the Movement Disorder Society
|June 27, 2012
PubMed
Abstract

Insights

The Addenbrooke's Cognitive Examination-Revised effectively screens for mild cognitive impairment (MCI) in Parkinson's disease (PD). This tool helps identify cognitive issues impacting behavior and quality of life in PD patients.

Area of Science:

  • Neurology
  • Cognitive Science

Background:

  • Cognitive impairment is a frequent complication of Parkinson's disease (PD), manifesting even in early stages.
  • There is a need for validated screening tools to detect cognitive deficits in PD patients.

Purpose of the Study:

  • To evaluate the Addenbrooke's Cognitive Examination-Revised (ACE-R) as a screening tool for mild cognitive impairment (MCI) in Parkinson's disease (PD).
  • To examine the association between ACE-R performance and behavioral and quality of life measures in PD.

Main Methods:

  • A population-representative incident cohort of 132 Parkinson's disease patients was assessed using the ACE-R.
  • Correlations were analyzed between ACE-R scores and the Parkinson's Disease Cognitive Rating Scale, Cambridge Behavioral Inventory-Revised, and Parkinson's Disease Questionnaire-39 in 219 patients.

Main Results:

  • Twenty-two percent of PD patients met the criteria for MCI.
  • Receiver operating curve analysis indicated an area under the curve of 0.81 for the ACE-R in detecting MCI.
  • A cutoff score of <89 on the ACE-R demonstrated 69% sensitivity and 84% specificity.

Conclusions:

  • The ACE-R is a valuable screening instrument for identifying MCI in Parkinson's disease.
  • Poorer performance on the ACE-R is significantly linked to impaired behavior and reduced quality of life in individuals with PD.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...